Harvard Bioscience reports preliminary Q4 revenue $23.7M

Gross Margin of 60%, at the high end of the 58% to 60% guidance range, driven by an improved mix to higher margin product lines, as well as the benefit of prior cost reductions. Adjusted EBITDA of $3.8M, which reflects 27% growth year over year, driven by cost reduction, improved expense management and solid execution .”We’re pleased with our fourth quarter performance and excited to share an overview of our go-forward strategy,” said John Duke, CEO. “With a stronger foundation provided by our refinancing and strategic consolidation, we’re scaling our business model by focusing our priorities on the evolving needs of the life sciences industry. We are excited for what’s ahead and are confident we will drive year over year revenue growth and mid-to high-single digit adjusted EBITDA growth in 2026.”